FcγRIII blockade prevents anti-HLA–mediated platelet clearance in a humanized murine model of platelet transfusion refractoriness

L Lazaro Gil Gonzalez (Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Unity Health Toronto , Toronto, ON,) K Kevin Doyoon Won (Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Unity Health Toronto , Toronto, ON,) Z Zoya Tawhidi (Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Unity Health Toronto , Toronto, ON,) A Alequis Pavon Oro (Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Unity Health Toronto , Toronto, ON,) Y Yaima Tundidor Cabado (Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Unity Health Toronto , Toronto, ON,) Y Yoelys Cruz-Leal (Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Unity Health Toronto , Toronto, ON,) A Akash Gupta H Hanna Wabnitz (Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Unity Health Toronto , Toronto, ON,) U Ulrich J Sachs (Institute for Clinical Immunology, Transfusion Medicine, and Haemostasis, Justus Liebig University , Giessen,) R Rick Kapur (Sanquin Blood Supply Foundation) A Alan H Lazarus (Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Unity Health Toronto , Toronto, ON,)

Abstract

Abstract Immune platelet transfusion refractoriness (iPTR) is a major complication in transfusion medicine. Although anti-HLA antibodies are recognized contributors, the mechanisms by which they drive platelet clearance remain incompletely defined. We examined sera from 18 patients with iPTR and found that anti-HLA antibodies induced uptake of human platelets expressing the cognate HLA-A2 target antigen and platelet particles derived from these platelets. These sera also mediated clearance of transgenic mouse platelets expressing human HLA-A2. Using THP-1–CD16A macrophages, uptake of both platelets and platelet particles was mediated predominantly through FcγRIIIa, with a partial contribution from FcγRI and little to no role for FcγRII. To test this pathway in vivo, we used a reductionist humanized murine model of iPTR in which HLA-A2 transgenic mouse platelets sensitized with human iPTR sera were transfused into FcγR-humanized mice. In this model, FcγRIII blockade with 17C02-albumin prevented platelet clearance under the conditions tested. These findings extend previous FcγR studies in antibody-mediated platelet clearance to the alloimmune setting of iPTR and support further investigation of FcγRIII-dependent pathways in antibody-mediated PTR.

Article Details

Volume / Issue Vol. 215, Issue 7
Published July 10, 2026
ISSN 0022-1767
Publisher American Association of Immunologists

Authors (11)

L

Lazaro Gil Gonzalez

Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Unity Health Toronto , Toronto, ON,

K

Kevin Doyoon Won

Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Unity Health Toronto , Toronto, ON,

Z

Zoya Tawhidi

Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Unity Health Toronto , Toronto, ON,

A

Alequis Pavon Oro

Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Unity Health Toronto , Toronto, ON,

Y

Yaima Tundidor Cabado

Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Unity Health Toronto , Toronto, ON,

Y

Yoelys Cruz-Leal

Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Unity Health Toronto , Toronto, ON,

A

Akash Gupta

H

Hanna Wabnitz

Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Unity Health Toronto , Toronto, ON,

U

Ulrich J Sachs

Institute for Clinical Immunology, Transfusion Medicine, and Haemostasis, Justus Liebig University , Giessen,

R

Rick Kapur

Sanquin Blood Supply Foundation

A

Alan H Lazarus

Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Unity Health Toronto , Toronto, ON,